Posted from: Thursday, September 18, 2014 - 03:00 PM - Present

Striverdi Respimate Approved for the Treatment of COPD

July 31, 2014 - Striverdi Respimate (olodaterol) was approved by the FDA for maintenance treatment of airflow obstruction in patients who have chronic obstructive pulmonary disorder (COPD). Striverdi Respimate is manufactured by Boehringer Ingelheim and each inhaler will contain 60 puffs (30 doses) containing 2.5 micrograms of olodaterol per puff.


Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.


Last Updated Saturday, September 21, 2019 - 05:56 PM.